Does the media refer more to PMN or VALN?

In the previous week, Valneva had 11 more articles in the media than Promis Neurosciences. MarketBeat recorded 18 mentions for Valneva and 7 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.95 beat Valneva's score of 0.11 indicating that Promis Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Promis Neurosciences 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valneva 3 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, ZURA or PMN?

Zura Bio is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zura Bio N/A N/A -$99.35M -$1.09 N/A Promis Neurosciences N/A N/A -$39.72M -$14.51 N/A

Is ZURA or PMN more profitable?

Zura Bio's return on equity of -61.47% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Zura Bio N/A -61.47% -54.11% Promis Neurosciences N/A -237.99% -151.04%

Does the media favor ZURA or PMN?

In the previous week, Promis Neurosciences had 3 more articles in the media than Zura Bio. MarketBeat recorded 7 mentions for Promis Neurosciences and 4 mentions for Zura Bio. Promis Neurosciences' average media sentiment score of 0.95 beat Zura Bio's score of 0.34 indicating that Promis Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zura Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Promis Neurosciences 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, ANL or PMN?

Adlai Nortye has higher revenue and earnings than Promis Neurosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 106.00 -$35.53M N/A N/A Promis Neurosciences N/A N/A -$39.72M -$14.51 N/A

Is ANL or PMN more profitable?

Adlai Nortye's return on equity of 0.00% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Promis Neurosciences N/A -237.99% -151.04%

Does the media favor ANL or PMN?

In the previous week, Promis Neurosciences had 1 more articles in the media than Adlai Nortye. MarketBeat recorded 7 mentions for Promis Neurosciences and 6 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 1.45 beat Promis Neurosciences' score of 0.95 indicating that Adlai Nortye is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Promis Neurosciences 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is EVMN or PMN more profitable?

Evommune's return on equity of -62.63% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A -62.63% -40.55% Promis Neurosciences N/A -237.99% -151.04%

Does the media prefer EVMN or PMN?

In the previous week, Evommune had 8 more articles in the media than Promis Neurosciences. MarketBeat recorded 15 mentions for Evommune and 7 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.95 beat Evommune's score of -0.41 indicating that Promis Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Promis Neurosciences 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, MPLT or PMN?

Promis Neurosciences is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maplight Therapeutics N/A N/A -$161.15M -$40.99 N/A Promis Neurosciences N/A N/A -$39.72M -$14.51 N/A

Is MPLT or PMN more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Maplight Therapeutics N/A N/A N/A Promis Neurosciences N/A -237.99% -151.04%

Does the media refer more to MPLT or PMN?

In the previous week, Maplight Therapeutics had 1 more articles in the media than Promis Neurosciences. MarketBeat recorded 8 mentions for Maplight Therapeutics and 7 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.95 beat Maplight Therapeutics' score of 0.80 indicating that Promis Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Promis Neurosciences 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Promis Neurosciences (PMN) Competitors

$14.86 +0.07 (+0.47%)

Closing price 04:00 PM Eastern

Extended Trading

$14.88 +0.02 (+0.13%)

As of 05:05 PM Eastern

Compare

PMN vs. VALN, ZURA, ANL, EVMN, and MPLT

Should you buy Promis Neurosciences stock or one of its competitors? Promis Neurosciences's main competitors and comparable companies include Valneva (VALN), Zura Bio (ZURA), Adlai Nortye (ANL), Evommune (EVMN), and Maplight Therapeutics (MPLT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Promis Neurosciences compare to Valneva?

Promis Neurosciences (NASDAQ:PMN) and Valneva (NASDAQ:VALN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Promis Neurosciences has a net margin of 0.00% compared to Valneva's net margin of -88.87%. Valneva's return on equity of -107.63% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-237.99%	-151.04%
Valneva	-88.87%	-107.63%	-33.02%

In the previous week, Valneva had 11 more articles in the media than Promis Neurosciences. MarketBeat recorded 18 mentions for Valneva and 7 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.95 beat Valneva's score of 0.11 indicating that Promis Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Promis Neurosciences	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valneva	3 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Promis Neurosciences has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A
Valneva	$197.56M	3.42	-$130.33M	-$1.87	N/A

50.1% of Promis Neurosciences shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by insiders. Comparatively, 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Promis Neurosciences has a beta of -0.23, indicating that its share price is 123% less volatile than the broader market. Comparatively, Valneva has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Promis Neurosciences presently has a consensus target price of $31.50, indicating a potential upside of 111.98%. Valneva has a consensus target price of $11.98, indicating a potential upside of 68.02%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts plainly believe Promis Neurosciences is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Valneva	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Promis Neurosciences beats Valneva on 8 of the 15 factors compared between the two stocks.

How does Promis Neurosciences compare to Zura Bio?

Zura Bio (NASDAQ:ZURA) and Promis Neurosciences (NASDAQ:PMN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Zura Bio's return on equity of -61.47% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-61.47%	-54.11%
Promis Neurosciences	N/A	-237.99%	-151.04%

Zura Bio has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.23, suggesting that its stock price is 123% less volatile than the broader market.

Zura Bio is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

Zura Bio currently has a consensus price target of $14.00, suggesting a potential upside of 151.35%. Promis Neurosciences has a consensus price target of $31.50, suggesting a potential upside of 111.98%. Given Zura Bio's higher possible upside, equities research analysts clearly believe Zura Bio is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

In the previous week, Promis Neurosciences had 3 more articles in the media than Zura Bio. MarketBeat recorded 7 mentions for Promis Neurosciences and 4 mentions for Zura Bio. Promis Neurosciences' average media sentiment score of 0.95 beat Zura Bio's score of 0.34 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Promis Neurosciences	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.1% of Zura Bio shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 12.4% of Zura Bio shares are held by company insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Zura Bio beats Promis Neurosciences on 8 of the 14 factors compared between the two stocks.

How does Promis Neurosciences compare to Adlai Nortye?

Adlai Nortye (NASDAQ:ANL) and Promis Neurosciences (NASDAQ:PMN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 1.5% of Promis Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Promis Neurosciences had 1 more articles in the media than Adlai Nortye. MarketBeat recorded 7 mentions for Promis Neurosciences and 6 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 1.45 beat Promis Neurosciences' score of 0.95 indicating that Adlai Nortye is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Promis Neurosciences	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adlai Nortye has higher revenue and earnings than Promis Neurosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	106.00	-$35.53M	N/A	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

Adlai Nortye presently has a consensus target price of $24.25, indicating a potential upside of 83.02%. Promis Neurosciences has a consensus target price of $31.50, indicating a potential upside of 111.98%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts clearly believe Promis Neurosciences is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Adlai Nortye's return on equity of 0.00% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Promis Neurosciences	N/A	-237.99%	-151.04%

Adlai Nortye has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.23, meaning that its stock price is 123% less volatile than the broader market.

Summary

Adlai Nortye beats Promis Neurosciences on 7 of the 13 factors compared between the two stocks.

How does Promis Neurosciences compare to Evommune?

Evommune (NYSE:EVMN) and Promis Neurosciences (NASDAQ:PMN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

Evommune's return on equity of -62.63% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	-62.63%	-40.55%
Promis Neurosciences	N/A	-237.99%	-151.04%

50.1% of Promis Neurosciences shares are held by institutional investors. 31.1% of Evommune shares are held by company insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Evommune had 8 more articles in the media than Promis Neurosciences. MarketBeat recorded 15 mentions for Evommune and 7 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.95 beat Evommune's score of -0.41 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Promis Neurosciences	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evommune presently has a consensus target price of $43.25, indicating a potential upside of 196.31%. Promis Neurosciences has a consensus target price of $31.50, indicating a potential upside of 111.98%. Given Evommune's higher probable upside, research analysts plainly believe Evommune is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Promis Neurosciences has lower revenue, but higher earnings than Evommune. Evommune is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$10M	52.97	-$68.87M	-$11.03	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

Summary

Evommune beats Promis Neurosciences on 8 of the 13 factors compared between the two stocks.

How does Promis Neurosciences compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Promis Neurosciences (NASDAQ:PMN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Maplight Therapeutics currently has a consensus price target of $29.67, indicating a potential upside of 152.48%. Promis Neurosciences has a consensus price target of $31.50, indicating a potential upside of 111.98%. Given Maplight Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Maplight Therapeutics is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

50.1% of Promis Neurosciences shares are held by institutional investors. 3.8% of Maplight Therapeutics shares are held by insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Maplight Therapeutics had 1 more articles in the media than Promis Neurosciences. MarketBeat recorded 8 mentions for Maplight Therapeutics and 7 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.95 beat Maplight Therapeutics' score of 0.80 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Promis Neurosciences	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Promis Neurosciences is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

Maplight Therapeutics' return on equity of 0.00% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Promis Neurosciences	N/A	-237.99%	-151.04%

Summary

Maplight Therapeutics beats Promis Neurosciences on 9 of the 13 factors compared between the two stocks.

Get Promis Neurosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PMN vs. The Competition

Export

Metric	Promis Neurosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$133.29M	$3.71B	$6.97B	$13.05B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-1.02	10.68	269.86	25.30
Price / Sales	N/A	1,293.47	598.68	101.54
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	-25.62	17.49	13.08	6.33
Net Income	-$39.72M	-$13.32M	$3.45B	$347.70M
7 Day Performance	1.02%	1.77%	1.14%	1.08%
1 Month Performance	8.78%	1.63%	1.81%	1.04%
1 Year Performance	-5.65%	56.45%	67.69%	20.77%

Promis Neurosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PMN Promis Neurosciences	3.7437 of 5 stars	$14.86 +0.5%	$31.50 +112.0%	-15.5%	$133.29M	N/A	N/A	5	News Coverage Earnings Report Gap Up
VALN Valneva	2.4192 of 5 stars	$5.55 -0.7%	$11.98 +115.9%	-49.4%	$530.41M	$197.56M	N/A	700	Trending News Earnings Report Analyst Forecast Gap Up High Trading Volume
ZURA Zura Bio	2.6465 of 5 stars	$5.78 +4.0%	$14.00 +142.2%	+254.1%	$527.54M	N/A	N/A	3	Earnings Report Analyst Forecast
ANL Adlai Nortye	2.2101 of 5 stars	$13.09 +0.1%	$24.25 +85.3%	+679.4%	$523.20M	$5M	N/A	127	News Coverage Positive News Earnings Report
EVMN Evommune	2.5632 of 5 stars	$14.03 -1.3%	$43.25 +208.3%	N/A	$515.71M	$13M	N/A	45	News Coverage Analyst Revision Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PMN) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Promis Neurosciences (PMN) Competitors

PMN vs. VALN, ZURA, ANL, EVMN, and MPLT

How does Promis Neurosciences compare to Valneva?

Summary

How does Promis Neurosciences compare to Zura Bio?

Summary

How does Promis Neurosciences compare to Adlai Nortye?

Summary

How does Promis Neurosciences compare to Evommune?

Summary

How does Promis Neurosciences compare to Maplight Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN vs. The Competition

Promis Neurosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Promis Neurosciences (PMN) Competitors

PMN vs. VALN, ZURA, ANL, EVMN, and MPLT

How does Promis Neurosciences compare to Valneva?

Is PMN or VALN more profitable?

Does the media refer more to PMN or VALN?

Which has stronger earnings and valuation, PMN or VALN?

Do insiders and institutionals believe in PMN or VALN?

Which has more risk and volatility, PMN or VALN?

Do analysts prefer PMN or VALN?

Summary

How does Promis Neurosciences compare to Zura Bio?

Is ZURA or PMN more profitable?

Which has more volatility & risk, ZURA or PMN?

Which has stronger earnings and valuation, ZURA or PMN?

Do analysts prefer ZURA or PMN?

Does the media favor ZURA or PMN?

Do insiders & institutionals hold more shares of ZURA or PMN?

Summary

How does Promis Neurosciences compare to Adlai Nortye?

Do insiders & institutionals have more ownership in ANL or PMN?

Does the media favor ANL or PMN?

Which has higher earnings & valuation, ANL or PMN?

Do analysts recommend ANL or PMN?

Is ANL or PMN more profitable?

Which has more volatility and risk, ANL or PMN?

Summary

How does Promis Neurosciences compare to Evommune?

Is EVMN or PMN more profitable?

Do insiders & institutionals believe in EVMN or PMN?

Does the media prefer EVMN or PMN?

Do analysts prefer EVMN or PMN?

Which has preferable earnings & valuation, EVMN or PMN?

Summary

How does Promis Neurosciences compare to Maplight Therapeutics?

Do analysts rate MPLT or PMN?

Do institutionals and insiders believe in MPLT or PMN?

Does the media refer more to MPLT or PMN?

Which has stronger earnings and valuation, MPLT or PMN?

Is MPLT or PMN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN vs. The Competition

Promis Neurosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools